Beta

    fda approve camizestrant for advanced breast cancer

    Before Oct 1, 2026

    fda approve camizestrant for advanced breast cancer. Best Yes near 39¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 39¢ · Best No: 66¢ · 1 platform

    • Kalshi: Yes 39¢ / No 66¢
    LIVE

    Before Oct 1, 2026

    Volume

    $721

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Oct 1, 2026

    ~107 days left

    Category

    Culture

    39¢CHANCE OF YES37%63%
    Yes
    39¢
    Kalshi
    No
    66¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    39¢
    No
    66¢
    Vol
    $721
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Oct 1, 2026, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 39¢: exit costs ~1.67¢/contract
    Full calculator

    Market Details

    ResolutionResolves Oct 1, 2026
    Time Left107 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In